Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1

NCT06411288 is registered in ClinicalTrials.gov with Avidity Biosciences, Inc. as lead sponsor.

NCT NCT06411288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06411288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
Lead sponsor
Avidity Biosciences, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 30, 2024
Completion date
July 29, 2026
Enrollment
159 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

dm1, dystrophy myotonic, myotonia, myotonic disorders, myotonic dystrophy, myotonic dystrophy 1, myotonic dystrophy type 1 (dm1), myotonic muscular dystrophy, steinert, steinert disease